Very important to persist for tilmanocept to clearly be able to identify Lympho-myeloid pathotype in 2b biopsy trial as Lympho-myeloid is a clear precursor of being able to identity need for a biological in around 12 months for later RA claims/nda's
Expert Costantino Pitzalis gene trial: "baseline lympho-myeloid pathotype are significantly more likely to require biological therapy 12 months after diagnosis"
https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjUlfP9qMX6AhWbLUQIHbB2DvQ4KBAWegQIEhAB&url=https://www.qminnovation.co.uk/wp-content/uploads/2020/10/2019083_Pitzalis_flyer_19102020.pdf&usg=AOvVaw3kfBbNCn65RuWumH6birTg